Brain-Computer Interface: How It Works, Applications & Risks

Brain-computer interfaces (BCIs) are already helping people with paralysis move cursors and control robotic arms, but the technology faces real limitations and unanswered questions. This guide separates proven science from the hype, covering how BCIs work, who uses them, and what risks remain.

First BCI demonstration (Vidal, 1973): 1973 ·
FDA-approved BCI devices as of 2025: 0 ·
Neuralink’s first human implant: January 2024 ·
Number of BCI startups (estimated): over 30

The table above captures the field’s trajectory from early milestones to future market expectations.

What does a brain computer interface do?

A brain-computer interface creates a direct communication link between the brain’s electrical activity and an external device. PMC review of non-invasive BCIs defines a BCI as a system that decodes neural signals into commands — effectively allowing the brain to “talk” to a machine without using muscles or nerves.

How BCIs translate brain signals into commands

• Electrodes record neural activity from the brain.
• Algorithms decode the signals to identify the user’s intention.
• The decoded command is sent to an external device (cursor, prosthetic, wheelchair).

This process happens in real time. As Harvard Medical School explains, the core challenge is extracting meaningful patterns from noisy neural data — a problem BCIs solve with machine learning and signal processing.

Types of BCI systems (EEG, ECoG, intracortical)

• Non-invasive (EEG): Electrodes placed on the scalp. Low risk, lower signal resolution. Used in research and consumer headsets.
• Semi-invasive (ECoG): Electrodes placed under the skull but on the brain’s surface. Better signal, moderate risk.
• Fully invasive (intracortical): Electrodes inserted into brain tissue. Highest signal fidelity, highest surgical risk. Used in Neuralink and BrainGate trials.

The trade-off is between signal quality and invasiveness — a key tension driving BCI design.

How does a brain computer interface work?

BCIs follow a three-stage pipeline: signal acquisition, processing, and output. PMC review breaks down each stage.

Signal acquisition: EEG, ECoG, spikes

• EEG records voltage fluctuations from the scalp using non-invasive electrodes.
• ECoG uses a grid of electrodes placed directly on the brain’s surface.
• Intracortical arrays (like the Utah Array) record action potentials from individual neurons.

Each method trades safety for resolution. Georgia Tech research shows that non-invasive EEG can reliably detect motor imagery but struggles with fine-grained control.

Signal processing and feature extraction

• Raw signals are filtered to remove noise (e.g., eye blinks, muscle artifacts).
• Algorithms extract features such as frequency band power (mu, beta) or spike rates.
• Machine learning classifiers map these features to user intentions (e.g., “move left”).

Command translation and output

• The decoded intention becomes a control command for the target device.
• Output examples: moving a cursor, typing a letter, driving a wheelchair, operating a robotic arm.

The pattern is clear: each stage introduces potential errors, making pipeline reliability the field’s central engineering challenge.

What is a real world example of BCI?

Real-world BCI applications have moved from lab demonstrations to human trials. Three notable examples show the range of what’s possible today.

Neuralink’s Noland Arbaugh case

In January 2024, Neuralink implanted its first human participant, Noland Arbaugh, who has quadriplegia. According to Reuters, the implant allowed Arbaugh to control a computer cursor and play online chess. The company later reported that the device’s electrode threads had partially retracted, though the system remained functional. The study, registered as PRIME on ClinicalTrials.gov, is recruiting participants with spinal cord injury or ALS. A related area of medical technology research is What Are Stem Cells? Types, Sources and Uses Explained, which explores regenerative therapies that may complement neural repair.

EEG-based wheelchair control

Non-invasive BCIs have enabled users to steer a wheelchair using motor imagery. PMC review notes that EEG-based systems achieve accuracy around 80–90% in controlled lab settings, but reliability drops in real-world environments due to noise and user fatigue.

Communication aids for locked-in patients

For patients who cannot move or speak, BCIs offer a lifeline. The BrainGate consortium demonstrated that people with tetraplegia could type at speeds of up to 15 characters per minute using a cortical implant. Research from PMC confirms that such systems restore basic communication and sense of agency.

The implication: each success story is tempered by limitations that prevent routine clinical deployment.

How close are we to the brain computer interface?

Despite decades of research, no fully implanted BCI has yet received FDA approval for general use. U.S. FDA guidance states that safety and effectiveness must be proven through rigorous clinical investigation.

Current clinical trials and regulatory hurdles

• Neuralink’s PRIME study is the high-profile invasive trial, but others exist.
• Synchron’s Stentrode — implanted via blood vessels — received FDA breakthrough designation in 2021 and is in early feasibility studies.
• Blackrock Neurotech’s Utah Array has been used in multiple clinical studies but remains investigational.

As of 2025, FDA has approved zero fully implanted BCIs for commercial use. The breakthrough designation pathway accelerates development but doesn’t guarantee approval.

Recent advances (2020–2025)

• 2021: Synchron’s Stentrode first-in-human study published results for motor restoration.
• 2024: Neuralink first human implant.
• 2025: Neuralink receives FDA breakthrough device designation for speech restoration BCI (Reuters).

For context on neurological conditions that these devices aim to treat, Postural Orthostatic Tachycardia Syndrome Symptoms – Key Signs and Triggers illustrates the types of autonomic disorders where neural monitoring could eventually play a role.

Expected timeline for consumer BCIs

Most experts predict that non-invasive BCI headsets for gaming, wellness, or productivity could reach consumers within the next 3–5 years. Invasive medical BCIs for paralysis, however, are at least a decade away from widespread clinical adoption. PMC analysis emphasizes that regulatory and safety hurdles remain the primary blockers.

The catch: even optimistic timelines depend on trial outcomes that are years from completion.

What are the negatives of BCI?

Brain-computer interfaces carry significant risks that range from physical to ethical. The trade-off between benefit and harm remains the central debate in neurotechnology.

Medical risks of invasive surgery

• Infection, brain tissue damage, and inflammation from electrode insertion.
• Signal degradation over time due to scar tissue formation (glial encapsulation).
• Risk of stroke or hemorrhage when implanting deep brain electrodes.

PMC research documents that BCI implants trigger an immune response that can reduce signal quality within months.

Data privacy and security

• BCI data contains intimate neural information that could be hacked or misused.
• Unlike passwords, brain patterns cannot be easily reset if stolen.
• Legal frameworks for neural data protection are still emerging.

Ethical and social concerns

• Potential for cognitive enhancement inequality — only the wealthy could afford enhancements.
• Loss of autonomy if BCIs are used for surveillance or behavioral manipulation.
• Psychological impact: users may feel tethered to the device or fear loss of self.

How to evaluate a brain-computer interface device

If you’re considering a BCI — for research, therapy, or investment — three steps can help distinguish credible options from hype.

1. Check the regulatory status: Is the device cleared by a national regulatory body (FDA, CE, TGA)? Look for clinical trial registration on ClinicalTrials.gov.
2. Assess the evidence: What peer-reviewed studies support the claims? Avoid vendor-only white papers. Look for replication by independent labs.
3. Understand the form factor and risk: Non-invasive (EEG) is low risk, low resolution — good for research or rehabilitation. Invasive (implant) is high risk, high resolution — only justified for severe medical need.

The pattern: rigorous due diligence is essential because marketing claims often outpace clinical evidence.

Timeline of BCI development

Key milestones show how the field evolved from basic neuroscience to human trials in less than a century.

• 1924 — Hans Berger records first human EEG (PMC review)
• 1973 — Jacques Vidal coins “brain-computer interface” (PMC review)
• 1998 — First intracortical BCI implant in a human (Kennedy et al.) (PMC review)
• 2006 — BrainGate trial demonstrates cursor control (PMC review)
• 2024 — Neuralink’s first human implant (Noland Arbaugh) (Reuters)

The pace has accelerated, but the road from first concept to clinical reality has taken over 50 years.

What this means: the distance between breakthrough headlines and bedside availability remains measured in decades, not years.

What we know and what remains unclear

Confirmed facts

• EEG-based BCIs can control wheelchairs and cursors (PMC review)
• Intracortical BCIs restore voluntary movement in paralyzed patients
• Non-invasive BCIs are available for research and hobbyist use (OpenBCI)

What’s still unclear

• Long-term safety and reliability of fully implanted BCIs
• Feasibility of consumer-grade mind-reading devices
• Ability to restore complex cognitive functions (memory, emotion)

Expert perspectives on BCI

“The ability to decode neural activity and translate it into movement is a profound step forward for people with paralysis.”

— Dr. John Donoghue, Brown University, BrainGate project (PMC review)

“Our goal with Neuralink is to treat a wide range of neurological conditions, from paralysis to memory loss.”

— Elon Musk, Neuralink co-founder (Neuralink blog)

“We have shown that people with tetraplegia can control a robotic arm with thought alone.”

— Dr. Jennifer Collinger, University of Pittsburgh (PMC review)

Summary

Brain-computer interfaces are no longer science fiction. They have enabled people to move cursors, type letters, and control robotic arms with their thoughts alone. But the hype often outpaces the evidence. The field has produced zero FDA-approved fully implanted devices after 50 years of research. Surgical risks, signal degradation, and ethical landmines remain unsolved. For patients with severe paralysis, the benefit may justify the risk — but for the general public, the promise of “mind reading” remains far off. For researchers and investors, the choice is clear: back technologies with regulatory momentum (like Synchron’s stent-electrode or Neuralink’s breakthrough designation) rather than inflated marketing claims.

Understanding how a brain-computer interface interacts with neural tissue requires a solid grasp of the parts of the brain and their specific functions.

Frequently asked questions